TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04669171: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Sponsor: Enterome · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,924,230

Rescue Site Savings

+$1,256,640

Unlock Full NCT04669171 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04669171 Rescue Dossier →